-
Study aim
-
Determining effect of curcumin-piperine drug on Pseudomonas infection and clinical symptoms of cystic fibrosis patients
-
Design
-
A clinical trial with a control group, with parallel groups, double-blind, randomized,
-
Settings and conduct
-
Study population is the patients referred to the cystic fibrosis clinic in Akbar Children's Hospital. Patients are divided into case and control groups. Curcumin-piperine is given to case group and placebo with the usual treatments is given to control group . The duration of the treatment period will be 3 months. The results will be checked at the beginning and end of the treatment.
-
Participants/Inclusion and exclusion criteria
-
Entry conditions: Cystic fibrosis patients who have been diagnosed based on clinical symptoms and sweat test, 5 years and above, Have pulmonary and gastrointestinal problems, able to perform the spirometry maneuver and have at least FEV1≥ 30% based on normal population based on age, gender,height, Percentage of oxygen saturation based on pulse oximetry be≥90% at room temperature,be clinically stable, Informed consent has been obtained from the patients,Do not have heart,liver,kidney failure, Do not have celiac disease, No evidence of acute pulmonary exacerbation that requiring hospitalization in last4 weeks, Do not have evidence of severe complications of pulmonary disease including severe hemoptysis or pneumothorax during last 2 months
-
Intervention groups
-
Intervention group: the intervention group are cystic fibrosis patients with pseudomonas infection who are treated with curcumin-piperine in addition to the usual treatments for cystic fibrosis.control group are patients with cystic fibrosis who are treated with placebo in addition to the usual treatments of cystic fibrosis.
-
Main outcome variables
-
Clinical symptoms of patients,Pulmonary symptoms,Pseudomonas pulmonary infection,Weight,Height,Body mass index,Patients' quality of life